Satisfactory chemotherapy of breast cancer remains to be a great challenge in both experimental and clinical practice. Here in our study, we successfully developed a mixed drug delivery system composed of high density lipoprotein and calcium carbonate nanoparticles. The well-defined calcium carbonate nanoparticles served as a skeleton material to load anticancer drug doxorubicin, while high density lipoprotein served as a coating material to increase the stability and biocompatibility of the as-prepared mixed drug delivery system. Our experimental results indicated that the doxorubicin loading efficiency of HDL/CC nanoparticles was relatively high that is beneficial for the following administration. On the other hand, drug loaded HDL/CC/DOX nanoparticles can increase the uptake ratio of doxorubicin into breast cancer cells (MCF-7) compared with bare CC/DOX nanoparticles. Moreover, the in vivo tumor homing ability of HDL/CC nanoparticles as also superior than bare CC/DOX nanoparticles. Thus, HDL/CC/DOX nanoparticles exhibited stronger anticancer activity in vitro than free DOX or CC/DOX nanoparticles with minimized toxic side effects and preferable tumor-suppression capability on tumor-bearing nude mice model, which holds the potential to be further developed as a promising drug delivery system to be administered in clinic.
PalumboABringhenSCaravitaT, et al.Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet2016;
367: 825–831.
2.
TangDZhaoXYangT, et al.Paclitaxel prodrug based mixed micelles for tumor-targeted chemotherapy. RSC Adv2018;
8: 380–389.
3.
XiongHDuSZhangP, et al.Primary tumor and pre-metastatic niches co-targeting “peptides-lego” hybrid hydroxyapatite nanoparticles for metastatic breast cancer treatment. Biomater Sci2018;
6: 2591–2604.
4.
XiongHNiJJiangZ, et al.Intracellular self-disassemble polysaccharide nanoassembly for multi-factors tumor drug resistance modulation of doxorubicin. Biomater Sci2018;
6: 2527–2540.
5.
HanHSThambiTChoiKY, et al.Bioreducible shell-cross-linked hyaluronic acid nanoparticles for tumor-targeted drug delivery. Biomacromolecules2016;
16: 447–456.
6.
LeeJJLeeSYParkJH, et al.Cholesterol-modified poly(lactide-co-glycolide) nanoparticles for tumor-targeted drug delivery. Int J Pharm2016;
509: 483–491.
7.
CurtiBD.Physical barriers to drug delivery in tumors. Crit Rev Oncol Hematol1993;
14: 29–39.
8.
HenkeERoehrigFHoffmannH, et al.266 Auxiliar treatment by targeting the extracellular matrix to improve drug delivery and therapeutic response. Eur J Cancer2014;
50: 89–2.
9.
ZhangJZhouWWangX, et al.The CRISPR-Cas9 system: a promising tool for discovering potential approaches to overcome drug resistance in cancer. RSC Adv2018;
8: 33464–33472.
10.
LiangPCChenYCChi-FengC, et al.Doxorubicin-modified magnetic nanoparticles as a drug delivery system for magnetic resonance imaging-monitoring magnet-enhancing tumor chemotherapy. Int J Nanomed2016;
11: 2021–2037.
11.
XuanHWUSDuX.Gated mesoporous carbon nanoparticles as drug delivery system for stimuli-responsive controlled release. Carbon2016;
101: 135–142.
12.
ChenTWeiWHongX, et al.Intelligent Drug Delivery System Based on Mesoporous Silica Nanoparticles Coated with an Ultra-pH-Sensitive Gatekeeper and Poly(ethylene glycol). ACS Macro Lett2016;
5: 55–58.
13.
SongM-MXiangH-HFeiM-Y, et al.Facile fabrication of water-dispersible nanocomposites based on hexa-peri-hexabenzocoronene and Fe3O4 for dual mode imaging (fluorescent/MR) and drug delivery. RSC Adv2018;
8: 40554–40563.
14.
YueJWangZShaoD, et al.Cancer cell membrane-modified biodegradable mesoporous silica nanocarriers for berberine therapy of liver cancer. RSC Adv2018;
8: 40288–40297.
15.
WangZWangCFangY, et al.Color-tunable AIE-active conjugated polymer nanoparticles as drug carriers for self-indicating cancer therapy via intramolecular FRET mechanism. Polym Chem2018;
9: 3205–3214.
16.
ZhangMHeJJiangC, et al.Plaque-hyaluronidase-responsive high-density-lipoprotein-mimetic nanoparticles for multistage intimal-macrophage-targeted drug delivery and enhanced anti-atherosclerotic therapy. Int J Nanomed2017;
12: 533–558.
17.
SuFKozakKRImaizumiS, et al.
Apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides inhibit tumor development in a mouse model of ovarian cancer. Proc Natl Acad Sci USA2010;
107: 19997–20002.
18.
LiuJ.Tumor targeting effects of a novel modified paclitaxel-loaded discoidal mimic high density lipoproteins. Drug Deliv2013;
20: 356–363.
19.
MurakamiTWijagkanalanWHashidaM, et al.Intracellular drug delivery by genetically engineered high-density lipoprotein nanoparticles. Nanomedicine2010;
5: 867–879.
20.
YuanYWangWWangB, et al.Delivery of hydrophilic drug doxorubicin hydrochloride-targeted liver using apoAI as carrier. J Drug Target2013;
21: 367–374.
21.
ChenWLYangSDLiF, et al.Programmed pH/reduction-responsive nanoparticles for efficient delivery of antitumor agents in vivo. Acta Biomater2018;
81: 219–230.
22.
ZhaoXTangDYangT, et al.Facile preparation of biocompatible nanostructured lipid carrier with ultra-small size as a tumor-penetration delivery system. Colloids Surf B Biointerfaces2018;
170: 355–363.
23.
Wang C, Chen S, Wang Y, et al. Lipase-Triggered Water-Responsive “Pandora's Box” for Cancer Therapy: Toward Induced Neighboring Effect and Enhanced Drug Penetration. Advanced Materials 2018; 30: 1706407.
24.
MengL-XRenQMengQ, et al.Trastuzumab modified silica nanoparticles loaded with doxorubicin for targeted and synergic therapy of breast cancer. Artif Cells Nanomed Biotechnol2018;
46: 5556–5563.
25.
WuHZhaoYMuX, et al.A silica -polymer composite nano system for tumor-targeted imaging and p53 gene therapy of lung cancer. J Biomater Sci Polym Ed2015;
26: 384–400.
26.
YuYZhangZWangY, et al.A new NIR-triggered doxorubicin and photosensitizer indocyanine green co-delivery system for enhanced multidrug resistant cancer treatment through simultaneous chemo/photothermal/photodynamic therapy. Acta Biomater2017;
59: 170–180.
27.
WangCLiuXChenS, et al.Facile preparation of phospholipid -amorphous calcium carbonate hybrid nanoparticles: toward controllable burst drug release and enhanced tumor penetration. Chem Commun2018;
54: 13080–13083.
28.
KongGBraunRDDewhirstMW.Hyperthermia Enables Tumor-specific Nanoparticle Delivery: Effect of Particle Size. Cancer Res2000;
60: 4440–4445.
29.
PerryJLReuterKGLuftJC, et al.Desimone, Mediating Passive Tumor Accumulation through Particle Size, Tumor Type, and Location. Nano Lett2017;
17: 2879–2886.
30.
LDMDengZYu, et al.Biocompatible and Stable GO-Coated Fe3O4 Nanocomposite: A Robust Drug Delivery Carrier for Simultaneous Tumor MR Imaging and Targeted Therapy. ACS Biomater Sci Eng2018;
4: 2143–2154.
31.
WangCHanMLiuX, et al.Mitoxantrone-preloaded water-responsive phospholipid-amorphous calcium carbonate hybrid nanoparticles for targeted and effective cancer therapy. Int J Nanomed2019;
14: 1503–1517.
32.
WangWChenKSuY, et al.Lysosome-Independent Intracellular Drug/Gene Codelivery by Lipoprotein-Derived Nanovector for Synergistic Apoptosis-Inducing Cancer-Targeted Therapy. Biomacromolecules2018;
19: 438–448.
33.
HagaNFujitaNTsuruoT.Mitochondrial aggregation precedes cytochrome c release from mitochondria during apoptosis. Oncogene2003;
22: 5579–5585.
34.
LiangWCaiAChenG, et al.Shikonin induces mitochondria-mediated apoptosis and enhances chemotherapeutic sensitivity of gastric cancer through reactive oxygen species. Sci Rep2016;
6: 38267.
